Data/Analytics


U.S. drug spend jumped 12% in 2015

U.S. drug spend jumped 12% in 2015

2015 marks the second straight double digit increase in spend, which was driven by recent launches and specialty brands.

Five things for pharma marketers to know: Friday, April 8, 2016

Five things for pharma marketers to know: Friday, April 8, 2016

Analyst survey says docs want outcomes benefit from PCSK9s; Allergan licenses early-stage Alzheimer's drugs; Pfizer and IBM partner in Parkinson's disease

Eli Lilly's failed trial could spell the end for CETP inhibitors

Eli Lilly's failed trial could spell the end for CETP inhibitors

The results of a failed trial for Lilly's CEPT inhibitor has analysts saying there is little hope for Merck's drug in the same class.

Healthcare industry seeks to reform its position as hacking target

Healthcare industry seeks to reform its position as hacking target

Given the value of its data and its relatively backward security measures, the healthcare industry has become a prime target for hackers. But industry experts say changes are afoot.

Easy navigation beats out trustworthiness for health info, survey finds

Easy navigation beats out trustworthiness for health info, survey finds

Consumers are more likely to use health information websites they find easier to navigate than those perceived as trustworthy, like government sites, new research shows.

Five things for pharma marketers to know: Tuesday, March 1, 2016

Five things for pharma marketers to know: Tuesday, March 1, 2016

Analysis questions Addyi's effectiveness; Horizon is subpoenaed about its patient assistance programs; AstraZeneca sells non-U.S. rights to constipation drug

Five things for pharma marketers to know: Thursday, December 3, 2015

Five things for pharma marketers to know: Thursday, December 3, 2015

Healthcare spending rose in 2014; Publicis reorganizes its agency network; proposed New Jersey bill would punish drugmakers that move abroad

Data Management: Not If, But When

Data Management: Not If, But When

Healthcare may seem to have been unscarred by the ongoing rash of high-profile cyber-attacks, at least compared with retail and financial organizations. But to hear security pros tell it, the industry is increasingly finding itself as much of a target as companies in other sectors—if not more of one. Karen Epper Hoffman surveys the potential damage

IMS Health: Drug spend will steadily rise through 2020

IMS Health: Drug spend will steadily rise through 2020

Specialty medicines will keep drug spend trending upward through the next five years.

Is pharma's access to physicians decreasing or increasing?

Is pharma's access to physicians decreasing or increasing?

A pair of surveys paint a complicated picture of what direction pharma access to healthcare providers is going.